SAN FRANCISCO and SAN DIEGO, Sept. 19, 2016 /PRNewswire/ -- IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough small molecule synthetic lethality and immune-oncology therapies, today announced that it has been named by FierceBiotech as one of 2016's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
"We are honored to be selected into the Fierce 15 class of 2016 and recognized for our work in the oncology field, particularly in the area of synthetic lethality and cancer immunotherapy," commented Yujiro S. Hata, Chief Executive Officer of IDEAYA Biosciences. "This award reflects the quality of our scientific staff and advisors and the transformative potential of the programs we are pursuing to improve cancer care for patients."
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's fourteenth annual Fierce 15 selection.
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at https://pages.questexweb.com/FierceBiotech-Newsletter-Signup.html.
About IDEAYA Biosciences
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and San Diego, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery. For more information, please visit www.ideayabio.com.